Search
Now showing items 1-10 of 59
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.
(American Society for Microbiology., 2005)
In human immunodeficiency virus type 1 (HIV-1) subtype B infections, the emergence of viruses able to use
CXCR4 as a coreceptor is well documented and associated with accelerated CD4 decline and disease progression.
However, ...
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate Human Immunodeficiency Virus Type 1 vaccines.
(American Society for Microbiology., 2005)
No abstract available.
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.
(Plos., 2013)
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine. We previously identified a ...
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape.
(Nature Publishing Group., 2012)
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been unsuccessful, a minority of individuals ...
Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop.
(American Society for Microbiology., 2010)
The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine field. We
have identified a subtype C HIV-1-superinfected individual, CAP256, with high-level BCN activity, and ...
The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection.
(American Society for Microbiology., 2011)
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals is needed to
guide vaccine design and immunization strategies. Here we used a large panel of 44 HIV-1 envelope variants
(subtypes ...
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
(Elsevier, 2008)
Identifying the earliest neutralizing antibody specificities that are elicited following infection or vaccination
by HIV-1 is an important objective of current HIV/AIDS vaccine research. We have shown previously ...
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
(American Society for Microbiology., 2009)
We identified three cross-neutralizing plasma samples with high-titer anti-membrane proximal external
region (MPER) peptide binding antibodies from among 156 chronically human immunodeficiency virus type
1-infected ...
Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point.
(American Society for Microbiology., 2008)
It is unknown whether patterns of human immunodeficiency virus (HIV)-specific T-cell responses during acute infection may influence the viral set point and the course of disease. We wished to establish whether the magnitude ...
Structure of an N276-dependent HIV-1 neutralizing antibody targeting a rare V5 glycan hole adjacent to the CD4 binding site.
(American Society for Microbiology., 2016)
Abstract available in pdf.